UNASSIGNED: : A total of 24 adult male Wistar-Albino rats were equally and randomly divided into four groups. CBZ (Jevtana, Sanofi-Aventis USA) was intraperitoneally administered to Groups 2, 3, and 4 at doses of 0.5, 1.0, and 1.5 mg/kg/week, respectively, for 4 consecutive weeks; Group 1 received only i.p. saline at the same time. At the end of the study, the animals were sacrificed and their cochlea removed for histopathological examination.
UNASSIGNED: : Intraperitoneal administration of CBZ exerted an ototoxic effect on rats, and the histopathological results became worse in a dose-dependent manner (P < 0.05).
UNASSIGNED: : Our findings suggest that CBZ may be an ototoxic agent and can damage the cochlea. More clinical studies should be conducted to understand its ototoxicity.
■:将24只成年雄性Wistar-Albino大鼠随机平均分为4组。CBZ(Jevtana,Sanofi-AventisUSA)以0.5、1.0和1.5mg/kg/周的剂量腹膜内给予第2、3和4组,分别,连续4周;第1组仅同时接受腹膜内生理盐水。在研究结束时,处死动物,取出它们的耳蜗进行组织病理学检查。
■:腹腔注射CBZ对大鼠有耳毒性作用,组织病理学结果呈剂量依赖性恶化(P<0.05)。
■:我们的研究结果表明,CBZ可能是一种耳毒剂,会损害耳蜗。应进行更多的临床研究以了解其耳毒性。